PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology
Diagnostics · 10.08.2024 · 14 (16) · 1739
DOI: 10.3390/diagnostics14161739 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 10.08.2024. Verfasst von Stephanie M Eastwood und 10 weiteren Autor:innen. Beteiligte Einrichtung: C2N Diagnostics, 4340 Duncan Avenue, Suite 110, Saint Louis, MO 63110, USA. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, BrightFocus Foundation, NIH-SBIR.
Abstract (Originalsprache)
Alzheimer’s disease (AD) is a progressive irreversible neurodegenerative disorder that represents a major global public health concern. Traditionally, AD is diagnosed using cerebrospinal fluid biomarker analysis or brain imaging modalities. Recently, less burdensome, more widely available blood biomarker (BBM) assays for amyloid-beta (Aβ42/40) and phosphorylated-tau concentrations have been found to accurately identify the presence/absence of brain amyloid plaques and tau tangles and have helped to streamline AD diagnosis. However, few BBMs have been rigorously analytically validated. Herein, we report the analytical validation of a novel liquid chromatography–tandem mass spectrometry (LC-MS/MS) multiplex method for quantifying plasma phosphorylated-tau217 (p-tau217) and non-phosphorylated-tau217 (np-tau217) peptide concentrations. We combined the p-tau217/np-tau217 concentrations ratio (%p-tau217) and the previously validated LC-MS/MS multiplex assay for plasma Aβ42/40 into a new multianalyte assay with algorithmic analysis (MAAA; PrecivityAD2™ test) that identifies brain amyloid status based on brain amyloid positron emission tomography. We found (a) the %p-tau217 assay is precise, accurate, sensitive, and linear over a wide analytical measurement range, and free from carryover and interference; (b) the pre-analytical specimen collection, processing, storage, and shipping conditions that maintain plasma tau peptide stability; and (c) using the measured analytical imprecision for plasma Aβ42/40 and p-tau217/np-tau217 levels in a worst-case scenario model, the PrecivityAD2 test algorithm for amyloid pathology classification changed for only 3.5% of participants from brain amyloid positive to negative, or from negative to positive. The plasma sample preparation and LC-MS/MS methods underlying the PrecivityAD2 test are suitable for use in the clinical laboratory and valid for the test’s intended purpose: to aid in the diagnostic evaluation of individuals aged 55 and older with signs or symptoms of mild cognitive impairment or dementia.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- C2N Diagnostics, 4340 Duncan Avenue, Suite 110, Saint Louis, MO 63110, USA.
ORCID-Profile: Joel B Braunstein, Kevin E Yarasheski
Förderung
- NIA NIH HHS
- BrightFocus Foundation
- NIH-SBIR
- Alzheimer's Drug Discovery Foundation
- National Institute of Health
- Alzheimer’s Drug Discovery Foundation
- GHR Foundation
Zitieren
APA
Eastwood, S. M., Meyer, M. R., Kirmess, K. M., Wente-Roth, T. L., Irvin, F., Holubasch, M. S., Verghese, P. B., West, T., Braunstein, J. B., Yarasheski, K. E., & Contois, J. H. (2024). PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology. Diagnostics, 14(16), 1739. https://doi.org/10.3390/diagnostics14161739
Vancouver
Eastwood SM, Meyer MR, Kirmess KM, Wente-Roth TL, Irvin F, Holubasch MS, et al. PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology. Diagnostics. 2024;14(16):1739. doi:10.3390/diagnostics14161739
BibTeX
@article{Eastwood2024,
author = {Eastwood, Stephanie M and Meyer, Matthew R and Kirmess, Kristopher M and Wente-Roth, Traci L and Irvin, Faith and Holubasch, Mary S and Verghese, Philip B and West, Tim and Braunstein, Joel B and Yarasheski, Kevin E and Contois, John H},
title = {PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology},
journal = {Diagnostics},
year = {2024},
volume = {14},
number = {16},
pages = {1739},
doi = {10.3390/diagnostics14161739}
}
EUVIMED